A top-5 pharma used Within3's AI-powered Launch Intelligence to find mental health professionals as an unplanned prescriber segment.
With a compressed launch timeline for a newly acquired chronic disease therapy in an unfamiliar area, traditional segmentation left prescriber assumptions incomplete. Within3's Launch Intelligence platform unified referral data, online discussions and internal field insights with AI analytics. Insights surfaced in real time, avoiding the typical 6+ month delay of alternative testing, and revealed psychiatrists and therapists initiating treatment conversations.
Within3 is a medical affairs insights platform, used by pharma for virtual advisory boards and AI-supported insights reporting from field, trial and social data
This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.
Published by Within3 on its own site — read the original case study on within3.com ↗
Related use cases
- 01A top pharma used Within3's Launch Intelligence to address diagnostic delays for a chronic gastrointestinal condition.
- 02A midsize pharma's medical affairs team replaced manual insight reporting with Within3's AI-supported Insights Reporting.
- 03A global pharma unified fragmented medical and commercial intelligence on Within3 for a launch in an unfamiliar therapeutic area.
- 04A multinational pharma trained 700+ investigators and site staff for a Phase 3 breast cancer trial on Within3's learning hub.
- 05A medical affairs team ran two asynchronous virtual advisory boards across four European countries on Within3.
- 06A medical affairs team used a 17-day Within3 virtual advisory board to gather internal feedback on training.